CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 100 enrolled
Drug / intervention
Karismaother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06152718
NCT06152718N/ACompleted

New Regenerative and Anti-aging Medicine Approach Based on Single Strand Alpha-1 Collagen for Neo-collagenesis Induction: Clinical and Instrumental Experience of a New Medical Device for Dermal Regeneration (Karisma)

University of Palermo·interventional·Posted Dec 1, 2023·Updated Jan 12, 2026

In Brief

A clinical study evaluating Karisma for Skin Manifestations. Completed, enrolled 100 participants across 2 sites in 2 countries.

Detailed Summary

Purpose/Objectives of the Study: Regenerative medicine, as well as aesthetic plastic surgery and dermatology field persistently seeks innovative, minimally invasive interventions to enhance skin quality and mitigate signs of aging. This study evaluates the regenerative capabilities of a new medical device focused on dermal redensification, induced by injections of single-strand alpha 1 collagen, to verify its ability, in a specific formulation (contained within a matrix of hyaluronic acid and carboxymethylcellulose), to induce dermal stimulation in both scar outcomes and regenerative medicine applied to skin aging.

Study Details

Timeline

N/ACompletedFinished
202420252026
First PostedDec 1, 2023
Enrollment StartDec 1, 2023
Primary CompletionJun 30, 2024
Study CompletionDec 30, 2024
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 2.6 years ago

Interventions

Karismaother

Use of regenerative capabilities of a new medical device focused on dermal redensification, induced by injections of single-strand alpha 1 collagen